5-羧基酰氨基色胺马来酸盐 | 74885-09-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-羧基酰氨基色胺马来酸盐
• 中文别名: 3-(2-氨基乙基)-1H-吲哚-5-羧酸酰胺
• 英文名称: 5-carboxamidotryptamine
• 英文别名: 5-ct；[3H]-5-CT；5-carboxyamidotryptamine；3-(2-aminoethyl)-1H-indole-5-carboxamide；5‐carboxamidotryptamine
• CAS: 74885-09-9
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: WKZLNEWVIAGNAW-UHFFFAOYSA-N

物化性质

• 沸点：
  513.6±35.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)
• 溶解度：
  在水中的溶解度10 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  84.9
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-羧基酰氨基色胺马来酸盐 、 乙醛酸 在 氢氧化钾 作用下， 以 水 为溶剂， 反应 12.0h， 生成 6-carbamoyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-1-carboxylic acid
  参考文献：
  名称：

  Novel tetrahydro-β-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)

  摘要：

  A structure-activity relationship study was conducted on a series of tetrahydro-beta-carboline-1-carboxylic acid analogs in order to identify the key functionality responsible for activity against the mitogen-activated protein kinase-activated protein kinase 2 enzyme (MK-2). The compounds were further evaluated for their ability to inhibit TNF alpha production in U937 cells and in vivo. These compounds represent a novel structural class of compounds capable of inhibiting MK-2 with remarkable selectivity. (c) 2007 Elsevier Ltd. All rialuts reserved.

  DOI：

  10.1016/j.bmcl.2007.05.070
• 作为产物：
  描述：

  3-(2-aminoethyl)-1H-indole-5-carbonitrile 在 双氧水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.25h， 以7%的产率得到5-羧基酰氨基色胺马来酸盐
  参考文献：
  名称：

  A New Synthesis of the Potent 5-HT₁Receptor Ligand, 5-Carboxyamidotryptamine (5-CT)

  摘要：

  A short, convenient and relatively efficient synthesis of 5-CT is developed through a modified Michael reaction. This method represents a new general synthesis for tryptamines with labile indole substituents.

  DOI：

  10.1080/00397919308018587

文献信息

• Viral polymerase inhibitors
  申请人：——

  公开号：US20020065418A1

  公开（公告）日：2002-05-30

  A compound of the formula I: 1 wherein: X is CH or N; Y is O or S; Z is OH, NH 2 , NMeR 3 , NHR 3 ; OR 3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR 7 or CR 5 , wherein R 5 is H, halogen, or (C 1-6 ) alkyl and R 7 is H or (C 1-6 alkyl), with the proviso that X and A are not both N; R 6 is H, halogen, (C 1-6 alkyl) or OR 7 , wherein R 7 is H or (C 1-6 alkyl); R 1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C 1-3 )alkyl, (C 2-6 )alkenyl, phenyl(C 2-6 )alkenyl, (C 3-6 )cycloalkyl, (C 1-6 )alkyl, CF 3 , 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C 2-6 )alkenyl and phenyl(C 1-3 )alkyl), alkenyl, cycloalkyl, (C 1-6 )alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-3 )alkyl, (C 6-10 )bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R 3 is selected from H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, (C 3 6 )cycloalkyl(C 1-6 )alkyl, (C 6-10 )aryl, (C 6-10 )aryl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-6 )cycloalkyl(C 2-6 )alkenyl, (C 6-10 )aryl(C 2-6 )alkenyl, N{(C 1-6 )alkyl} 2 , NHCOO(C 1-6 )alkyl(C 6-10 )aryl, NHCO(C 6-10 )aryl, (C 1-6 )alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.

  该化合物的结构式为I:1，其中：X为CH或N；Y为O或S；Z为OH、NH2、NMeR3、NHR3、OR3或含有1至4个异原子（0、N和S）的5-或6-成员杂环，该杂环可选择性地与1至4个取代基取代；A为N、COR7或CR5，其中R5为H、卤素或（C1-6）烷基，R7为H或（C1-6）烷基，但X和A不能同时为N；R6为H、卤素、（C1-6）烷基或OR7，其中R7为H或（C1-6）烷基；R1选自包括含有1至4个异原子（O、N和S）的5-或6-成员杂环、苯基、苯基（C1-3）烷基、（C2-6）烯基、苯基（C2-6）烯基、（C3-6）环烷基、（C1-6）烷基、CF3、含有1至4个异原子（O、N和S）的9-或10-成员杂环的群体，其中该杂环、苯基、苯基（C2-6）烯基和苯基（C1-3）烷基、烯基、环烷基、（C1-6）烷基和杂环均可选择性地与1至4个取代基取代；R2选自（C1-6）烷基、（C3-7）环烷基、（C3-7）环烷基（C1-3）烷基、（C6-10）双环烷基、金刚烷基、苯基和吡啶基，所有这些基均可选择性地与1至4个取代基取代；R3选自H、（C1-6）烷基、（C3-6）环烷基、（C3-6）环烷基（C1-6）烷基、（C6-10）芳基、（C6-10）芳基（C1-6）烷基、（C2-6）烯基、（C3-6）环烷基（C2-6）烯基、（C6-10）芳基（C2-6）烯基、N(C1-6)烷基2、NHCOO(C1-6)烷基（C6-10）芳基、NHCO（C6-10）芳基、（C1-6）烷基-含有1至4个异原子（O、N和S）的5-或10-原子杂环和含有1至4个异原子（O、N和S）的5-或10-原子杂环；其中所述烷基、环烷基、芳基、烯基和杂环均可选择性地与1至4个取代基取代；n为零或1；或其可检测衍生物或盐。该发明的化合物可用作乙型肝炎病毒复制的抑制剂。该发明还提供了一种治疗或预防乙型肝炎病毒感染的方法。
• TETRAHYDROISOQUINOLINE DERIVATIVE
  申请人：Astellas Pharma Inc

  公开号：US20130317010A1

  公开（公告）日：2013-11-28

  To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-HT 5A receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a N atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-HT 5A receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.

  基于5-HT5A受体调节作用，提供一种预防或治疗痴呆症和精神分裂症的优秀药剂。发现一种四氢异喹啉衍生物，其特征在于酰基胍基团结合到四氢异喹啉环的N原子或类似物上，环状基团结合到不饱和环上，具有强效的5-HT5A受体调节作用和出色的药理作用。同时，发现该四氢异喹啉衍生物可用作治疗或预防痴呆症、精神分裂症等的药剂，因此本发明得以完成。
• Indole compounds and use thereof
  申请人：Glaxo Group Limited

  公开号：US04252803A1

  公开（公告）日：1981-02-24

  Compounds are disclosed of general formula (I): ##STR1## wherein R.sub.1 and R.sub.2 each independently represents a hydrogen atom, or an aryl, aralkyl, cycloalkyl, fluoroalkyl or alkyl group, which alkyl group is optionally substituted by an alkenyl group or by a group -OR.sub.7 or by ##STR2## where R.sub.7 and R.sub.8 each independently represents a hydrogen atom, an alkyl, aryl or aralkyl group; or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a saturated monocyclic 5 to 7 membered ring which may contain a further hetero function (viz--O--, --NH or ##STR3## R.sub.3 and R.sub.4 have the same meanings as R.sub.1 and R.sub.2 and may together form an aralkylidene group; R.sub.5 represents a hydrogen atom or an alkyl or aralkyl group; R.sub.6 represents a hydrogen atom or an aryl or C.sub.1 -C.sub.3 alkyl group; Alk represents an C.sub.1 -C.sub.4 alkylene group optionally substituted at one or more of its carbon atoms by one to three C.sub.1 -C.sub.3 alkyl groups; and X represents an oxygen or sulphur atom, and its physiologically acceptable salts, hydrates and bioprecursors. The indoles (I) may be prepared by combinations of reactions to introduce the desired substituents into suitable intermediates either before or after cyclization to form the indole nucleus. The compounds have selective actions on blood vessels and, in particular exhibit antihypertensive properties. They may be formulated in conventional manner as pharmaceutical compositions.

  化合物的通用结构式（I）已披露如下：##STR1## 其中，R.sub.1和R.sub.2各自独立地代表氢原子，或芳基、芳基烷基、环烷基、氟烷基或烷基基团，该烷基基团可选择地被烯基基团或基团-OR.sub.7或##STR2##所取代，其中R.sub.7和R.sub.8各自独立地代表氢原子、烷基、芳基或芳基烷基；或者R.sub.1和R.sub.2与它们连接的氮原子一起形成饱和的单环5到7成员环，该环可能包含进一步的杂原子功能（即-O-，-NH或##STR3## R.sub.3和R.sub.4的含义与R.sub.1和R.sub.2相同，它们可以一起形成芳基烷基亚甲基基团；R.sub.5代表氢原子或烷基或芳基烷基基团；R.sub.6代表氢原子或芳基或C.sub.1 -C.sub.3烷基基团；Alk代表一个C.sub.1 -C.sub.4烷基基团，该烷基基团在其一个或多个碳原子上可以被一个到三个C.sub.1 -C.sub.3烷基基团取代；X代表氧原子或硫原子，以及其生理上可接受的盐、水合物和生物前体。这些吲哚（I）可以通过反应的组合制备，将所需的取代基引入适当的中间体，无论是在环化形成吲哚核之前还是之后。这些化合物对血管具有选择性作用，特别表现出降压性能。它们可以按照传统方式制备成药物组合物。
• Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
  申请人：——

  公开号：US20040039044A1

  公开（公告）日：2004-02-26

  Novel aminoalkylpyrrolidine 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了新型氨基烷基吡咯啉5-HT7受体配体，制备这种配体的方法，用于制备受体配体的中间化合物，包括受体配体的药物组合物，以及利用受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。受体配体具有如下式（1）：其中式中的变量如本文所定义，并且包括其药用可接受的盐、溶剂化合物、活性代谢物或前药。
• Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
  申请人：——

  公开号：US20040044037A1

  公开（公告）日：2004-03-04

  Novel amidino-urea 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了一种新型的胍基脲5-HT7受体配体，以及制备这种配体的方法、在配体制备中有用的中间化合物、包括该受体配体的药物组合物，以及利用该受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。该受体配体具有化学式（1）：其中化学式变量如本文所定义，以及其药用盐、溶剂合物、活性代谢产物或前药。